A security alliance shaping the future of connected infrastructure

Tern plc

Device Authority’s KeyScaler platform has built its reputation on automating device identity at scale. Rather than relying on manual oversight, the system creates, rotates and retires digital identities across vast fleets of connected assets. For investors, the attraction is clear: this reduces exposure to breaches that often trace back to unmanaged or outdated credentials. But automation alone is only part of the equation. To be effective, these capabilities must be embedded into complex corporate ecosystems, which is where Optiv’s advisory strength comes into play.

The shift toward Zero Trust frameworks has sharpened the spotlight on machine identities. Unlike perimeter-based security, Zero Trust requires constant validation of every entity on the network. Device Authority’s identity-first approach fits directly into this narrative, while Optiv brings the experience needed to operationalise it for clients that span critical sectors such as energy, healthcare and manufacturing. The synergy points to a model where cyber defences are not bolted on as an afterthought but are woven into the operational fabric from the outset.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search